Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Abulencia, JP; Tien, N; McCarty, OJT; Plymire, D; Mousa, SA; Konstantopoulos, K
   Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis
   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
   
   J.P. Abulencia et al., "Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis", ART THROM V, 21(1), 2001, pp. 149-156
2. Sielecki, TM; Liu, J; Mousa, SA; Racanelli, AL; Hausner, EA; Wexler, RR; Olson, RE
   Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists
   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
   
   T.M. Sielecki et al., "Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists", BIOORG MED, 11(16), 2001, pp. 2201-2204
3. Hein, TW; Platts, SH; Waitkus-Edwards, KR; Kuo, L; Mousa, SA; Meininger, GA
   Integrin-binding peptides containing RGD produce coronary arteriolar dilation via cyclooxygenase activation
   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
   
   T.W. Hein et al., "Integrin-binding peptides containing RGD produce coronary arteriolar dilation via cyclooxygenase activation", AM J P-HEAR, 281(6), 2001, pp. H2378-H2384
4. Wilson, MF; Blum, R; Dandona, P; Mousa, SA
   Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and inflammatory markers: A model of human diseases
   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
   
   M.F. Wilson et al., "Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and inflammatory markers: A model of human diseases", CLIN EXP PH, 28(5-6), 2001, pp. 376-380
5. Mousa, SA; Zhang, Q; Sitte, N; Ji, RR; Stein, C
   beta-endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue
   JOURNAL OF NEUROIMMUNOLOGY
   
   S.A. Mousa et al., "beta-endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue", J NEUROIMM, 115(1-2), 2001, pp. 71-78
6. Mousa, SA; Forsythe, MS
   Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography
   THROMBOSIS RESEARCH
   
   S.A. Mousa e M.S. Forsythe, "Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography", THROMB RES, 104(1), 2001, pp. 49-56
7. Bishop, GG; McPherson, JA; Sanders, JM; Hesselbacher, SE; Feldman, MJ; McNamara, CA; Gimple, LW; Powers, ER; Mousa, SA; Sarembock, IJ
   Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit
   CIRCULATION
   
   G.G. Bishop et al., "Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit", CIRCULATION, 103(14), 2001, pp. 1906-1911
8. Mousa, SA; Bozarth, JM; Naik, UP; Slee, A
   Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic:distinct binding profile for Roxifiban
   BRITISH JOURNAL OF PHARMACOLOGY
   
   S.A. Mousa et al., "Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic:distinct binding profile for Roxifiban", BR J PHARM, 133(3), 2001, pp. 331-336
9. Rittner, HL; Brack, A; Machelska, H; Mousa, SA; Bauer, M; Schafer, M; Stein, C
   Opioid peptide-expressing leukocytes - Identification, recruitment, and simultaneously increasing inhibition of inflammatory pain
   ANESTHESIOLOGY
   
   H.L. Rittner et al., "Opioid peptide-expressing leukocytes - Identification, recruitment, and simultaneously increasing inhibition of inflammatory pain", ANESTHESIOL, 95(2), 2001, pp. 500-508
10. Kerr, JS; Slee, AM; Mousa, SA
    Small molecule alpha(v) integrin antagonists: novel anticancer agents
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    J.S. Kerr et al., "Small molecule alpha(v) integrin antagonists: novel anticancer agents", EXPERT OP I, 9(6), 2000, pp. 1271-1279
11. Mousa, SA
    Potential role of platelet glycoprotein IIb/IIIa antagonists in cerebrovascular disorders
    CNS DRUGS
    
    S.A. Mousa, "Potential role of platelet glycoprotein IIb/IIIa antagonists in cerebrovascular disorders", CNS DRUGS, 13(3), 2000, pp. 155-160
12. Mousa, SA; Khurana, S; Forsythe, MS
    Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography - Differentiation among glycoprotein IIb/IIIa antagonists
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    S.A. Mousa et al., "Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography - Differentiation among glycoprotein IIb/IIIa antagonists", ART THROM V, 20(4), 2000, pp. 1162-1167
13. Suich, DJ; Mousa, SA; Singh, G; Liapakis, G; Reisine, T; DeGrado, WF
    Template-constrained cyclic peptide analogues of somatostatin: Subtype-selective binding to somatostatin receptors and antiangiogenic activity
    BIOORGANIC & MEDICINAL CHEMISTRY
    
    D.J. Suich et al., "Template-constrained cyclic peptide analogues of somatostatin: Subtype-selective binding to somatostatin receptors and antiangiogenic activity", BIO MED CH, 8(9), 2000, pp. 2229-2241
14. Sielecki, TM; Wityak, J; Liu, J; Mousa, SA; Thoolen, M; Wexler, RR; Olson, RE
    Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    T.M. Sielecki et al., "Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists", BIOORG MED, 10(5), 2000, pp. 449-452
15. Mousa, SA; Forsythe, M; Bozarth, J; Jin, FQ; Confalone, PN
    Human platelet alpha IIb beta 3 integrin binding affinity end specificity of SJ874: antiplatelet efficacy versus aspirin
    CORONARY ARTERY DISEASE
    
    S.A. Mousa et al., "Human platelet alpha IIb beta 3 integrin binding affinity end specificity of SJ874: antiplatelet efficacy versus aspirin", CORON ART D, 11(7), 2000, pp. 563-570
16. Powell, JA; Mohamed, SN; Kerr, JS; Mousa, SA
    Antiangiogenesis efficacy of nitric oxide donors
    JOURNAL OF CELLULAR BIOCHEMISTRY
    
    J.A. Powell et al., "Antiangiogenesis efficacy of nitric oxide donors", J CELL BIOC, 80(1), 2000, pp. 104-114
17. Walton, HL; Corjay, MH; Mohamed, SN; Mousa, SA; Santomenna, LD; Reilly, TM
    Hypoxia induces differential expression of the integrin receptors alpha(v beta 3) and alpha(v beta 5) cultured human endothelial cells
    JOURNAL OF CELLULAR BIOCHEMISTRY
    
    H.L. Walton et al., "Hypoxia induces differential expression of the integrin receptors alpha(v beta 3) and alpha(v beta 5) cultured human endothelial cells", J CELL BIOC, 78(4), 2000, pp. 674-680
18. Mousa, MA; Mousa, SA
    Immunocytochemical studies of the gonadotropic cells in the pituitary gland of male mullet, Mugil cephalus, during the annual reproductive cycle in both natural habitat and captivity
    JOURNAL OF APPLIED ICHTHYOLOGY-ZEITSCHRIFT FUR ANGEWANDTE ICHTHYOLOGIE
    
    M.A. Mousa e S.A. Mousa, "Immunocytochemical studies of the gonadotropic cells in the pituitary gland of male mullet, Mugil cephalus, during the annual reproductive cycle in both natural habitat and captivity", J APP ICHTH, 16(3), 2000, pp. 98-103
19. Mousa, SA; Machelska, H; Schafer, M; Stein, C
    Co-expression of beta-endorphin with adhesion molecules in a model of inflammatory pain
    JOURNAL OF NEUROIMMUNOLOGY
    
    S.A. Mousa et al., "Co-expression of beta-endorphin with adhesion molecules in a model of inflammatory pain", J NEUROIMM, 108(1-2), 2000, pp. 160-170
20. Mousa, SA
    Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: Implications for management of vascular disorders
    SEMINARS IN THROMBOSIS AND HEMOSTASIS
    
    S.A. Mousa, "Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: Implications for management of vascular disorders", SEM THROMB, 26, 2000, pp. 39-46
21. Cue, D; Southern, SO; Southern, PJ; Prabhakar, J; Lorelli, W; Smallheer, JM; Mousa, SA; Cleary, PP
    A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin alpha 5 beta 1-fibronectin-M1 protein complexes
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    
    D. Cue et al., "A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin alpha 5 beta 1-fibronectin-M1 protein complexes", P NAS US, 97(6), 2000, pp. 2858-2863
22. Pitts, WJ; Wityak, J; Smallheer, JM; Tobin, AE; Jetter, JW; Buynitsky, JS; Harlow, PP; Solomon, KA; Corjay, MH; Mousa, SA; Wexler, RR; Jadhav, PK
    Isoxazolines as potent antagonists of the integrin alpha(v)beta(3)
    JOURNAL OF MEDICINAL CHEMISTRY
    
    W.J. Pitts et al., "Isoxazolines as potent antagonists of the integrin alpha(v)beta(3)", J MED CHEM, 43(1), 2000, pp. 27-40
23. Batt, DG; Petraitis, JJ; Houghton, GC; Modi, DP; Cain, GA; Corjay, MH; Mousa, SA; Bouchard, PJ; Forsythe, MS; Harlow, PP; Barbera, FA; Spitz, SM; Wexler, RR; Jadhav, PK
    Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3)
    JOURNAL OF MEDICINAL CHEMISTRY
    
    D.G. Batt et al., "Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3)", J MED CHEM, 43(1), 2000, pp. 41-58
24. Mousa, MA; Mousa, SA
    Implication of somatolactin in the regulation of sexual maturation and spawning of Mugil cephalus
    JOURNAL OF EXPERIMENTAL ZOOLOGY
    
    M.A. Mousa e S.A. Mousa, "Implication of somatolactin in the regulation of sexual maturation and spawning of Mugil cephalus", J EXP ZOOL, 287(1), 2000, pp. 62-73
25. Mousa, SA; Bozarth, JM; Forsythe, MS; Slee, A
    Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels
    CARDIOVASCULAR RESEARCH
    
    S.A. Mousa et al., "Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels", CARDIO RES, 47(4), 2000, pp. 819-826
26. McCarty, OJT; Mousa, SA; Bray, PF; Konstantopoulos, K
    Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions
    BLOOD
    
    O.J.T. McCarty et al., "Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions", BLOOD, 96(5), 2000, pp. 1789-1797
27. Colman, RW; Jameson, BA; Lin, YZ; Johnson, D; Mousa, SA
    Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis
    BLOOD
    
    R.W. Colman et al., "Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis", BLOOD, 95(2), 2000, pp. 543-550
28. Kim, S; Bell, K; Mousa, SA; Varner, JA
    Regulation of angiogenesis in vivo by ligation of integrin alpha 5 beta 1 with the central cell-binding domain of fibronectin
    AMERICAN JOURNAL OF PATHOLOGY
    
    S. Kim et al., "Regulation of angiogenesis in vivo by ligation of integrin alpha 5 beta 1 with the central cell-binding domain of fibronectin", AM J PATH, 156(4), 2000, pp. 1345-1362
29. Mousa, SA
    Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond
    DRUG DISCOVERY TODAY
    
    S.A. Mousa, "Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond", DRUG DISC T, 4(12), 1999, pp. 552-561
30. Mousa, SA
    Anti-integrins as a potential therapeutic target in angiogenesis
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    S.A. Mousa, "Anti-integrins as a potential therapeutic target in angiogenesis", EXPERT OP T, 9(9), 1999, pp. 1237-1248
31. Mousa, SA; Kapil, R; Mu, DX
    Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    S.A. Mousa et al., "Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459", ART THROM V, 19(10), 1999, pp. 2535-2541
32. Wityak, J; Tobin, AE; Mousa, SA; Wexler, RR; Olson, RE
    Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    J. Wityak et al., "Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate", BIOORG MED, 9(2), 1999, pp. 123-126
33. Confalone, PN; Jin, FQ; Mousa, SA
    Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    P.N. Confalone et al., "Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines", BIOORG MED, 9(1), 1999, pp. 55-58
34. Mousa, SA; Lorelli, W; Campochiaro, PA
    Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells
    JOURNAL OF CELLULAR BIOCHEMISTRY
    
    S.A. Mousa et al., "Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells", J CELL BIOC, 74(1), 1999, pp. 135-143
35. Kerr, JS; Wexler, RS; Mousa, SA; Robinson, CS; Wexler, EJ; Mohamed, S; Voss, ME; Devenny, JJ; Czerniak, PM; Gudzelak, A; Slee, AM
    Novel small molecule alpha v integrin antagonists: Comparative anti-cancerefficacy with known angiogenesis inhibitors
    ANTICANCER RESEARCH
    
    J.S. Kerr et al., "Novel small molecule alpha v integrin antagonists: Comparative anti-cancerefficacy with known angiogenesis inhibitors", ANTICANC R, 19(2A), 1999, pp. 959-968
36. Mousa, SA; Lorelli, W; Mohamed, S; Batt, DG; Jadhav, PK; Reilly, TM
    alpha(v)beta(3) integrin binding affinity and specificity of SM256 in various species
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    
    S.A. Mousa et al., "alpha(v)beta(3) integrin binding affinity and specificity of SM256 in various species", J CARDIO PH, 33(4), 1999, pp. 641-646
37. Barrett, JS; Yu, J; Kapil, R; Padovani, P; Brown, F; Ebling, WF; Corjay, MH; Reilly, TM; Bozarth, JM; Mousa, SA; Pieniaszek, HJ
    Disposition and exposure of the fibrinogen receptor antagonist XV459 on alpha(IIB)beta(3), binding sites in the guinea pig
    BIOPHARMACEUTICS & DRUG DISPOSITION
    
    J.S. Barrett et al., "Disposition and exposure of the fibrinogen receptor antagonist XV459 on alpha(IIB)beta(3), binding sites in the guinea pig", BIOPHARM DR, 20(6), 1999, pp. 309-318
38. Olson, RE; Sielecki, TM; Wityak, J; Pinto, DJ; Batt, DG; Frietze, WE; Liu, J; Tobin, AE; Orwat, MJ; Di Meo, SV; Houghton, GC; Lalka, GK; Mousa, SA; Racanelli, AL; Hausner, EA; Kapil, RP; Rabel, HR; Thoolen, MJ; Reilly, TM; Anderson, PS; Wexler, RR
    Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action
    JOURNAL OF MEDICINAL CHEMISTRY
    
    R.E. Olson et al., "Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action", J MED CHEM, 42(7), 1999, pp. 1178-1192
39. Mousa, SA; Mousa, MA
    Immunocytochemical and histological studies on the hypophyseal-gonadal system in the freshwater Nile tilapia, Oreochromis niloticus (L.), during sexual maturation and spawning in different habitats
    JOURNAL OF EXPERIMENTAL ZOOLOGY
    
    S.A. Mousa e M.A. Mousa, "Immunocytochemical and histological studies on the hypophyseal-gonadal system in the freshwater Nile tilapia, Oreochromis niloticus (L.), during sexual maturation and spawning in different habitats", J EXP ZOOL, 284(3), 1999, pp. 343-354
40. Mousa, MA; Mousa, SA
    Immunocytochemical study on the localization and distribution of the somatolactin cells in the pituitary gland and the brain of Oreochromis niloticus(Teleostei, Cichlidae)
    GENERAL AND COMPARATIVE ENDOCRINOLOGY
    
    M.A. Mousa e S.A. Mousa, "Immunocytochemical study on the localization and distribution of the somatolactin cells in the pituitary gland and the brain of Oreochromis niloticus(Teleostei, Cichlidae)", GEN C ENDOC, 113(2), 1999, pp. 197-211
41. Machelska, H; Cabot, PJ; Mousa, SA; Zhang, Q; Stein, C
    Pain control in inflammation governed by selectins
    NATURE MEDICINE
    
    H. Machelska et al., "Pain control in inflammation governed by selectins", NAT MED, 4(12), 1998, pp. 1425-1428
42. MOUSA SA; BOZARTH JM; EDWARDS S; CARROLL T; BARRETT J
    NOVEL TC-99M-LABELED PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS AS POTENTIAL IMAGING AGENTS FOR VENOUS AND ARTERIAL THROMBOSIS/
    Coronary artery disease
    
    S.A. Mousa et al., "NOVEL TC-99M-LABELED PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS AS POTENTIAL IMAGING AGENTS FOR VENOUS AND ARTERIAL THROMBOSIS/", Coronary artery disease, 9(2-3), 1998, pp. 131-141
43. MOUSA SA; MU DX; LUCCHESI B
    RESTORATION OF CORONARY FLOW BY POTENT PLATELET GPIIB IIIA ANTAGONISTWITHOUT EXOGENOUS THROMBOLYTICS/
    The FASEB journal
    
    S.A. Mousa et al., "RESTORATION OF CORONARY FLOW BY POTENT PLATELET GPIIB IIIA ANTAGONISTWITHOUT EXOGENOUS THROMBOLYTICS/", The FASEB journal, 12(5), 1998, pp. 4167-4167
44. HANTGAN RR; MOUSA SA
    INHIBITION OF PLATELET-MEDIATED CLOT RETRACTION BY INTEGRIN ANTAGONISTS
    The FASEB journal
    
    R.R. Hantgan e S.A. Mousa, "INHIBITION OF PLATELET-MEDIATED CLOT RETRACTION BY INTEGRIN ANTAGONISTS", The FASEB journal, 12(5), 1998, pp. 4176-4176
45. FORSYTHE M; MOUSA SA; KHURANA S
    COMPARATIVE EFFICACY OF DIFFERENT PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS ON PLATELET-MEDIATED CLOT STRENGTH USING TISSUE FACTOR-THROMBOELASTOGRAPHY/
    The FASEB journal
    
    M. Forsythe et al., "COMPARATIVE EFFICACY OF DIFFERENT PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS ON PLATELET-MEDIATED CLOT STRENGTH USING TISSUE FACTOR-THROMBOELASTOGRAPHY/", The FASEB journal, 12(5), 1998, pp. 4177-4177
46. LORELLI W; MOUSA SA; CAMPOCHIARO PA
    INTEGRINS IN HUMAN RETINAL PIGMENTED EPITHELIAL (RPE) CELLS - ROLE OFEXTRACELLULAR-MATRIX PROTEINS (ECMS) AND HYPOXIA ON THE SECRETION OF GROWTH-FACTORS
    The FASEB journal
    
    W. Lorelli et al., "INTEGRINS IN HUMAN RETINAL PIGMENTED EPITHELIAL (RPE) CELLS - ROLE OFEXTRACELLULAR-MATRIX PROTEINS (ECMS) AND HYPOXIA ON THE SECRETION OF GROWTH-FACTORS", The FASEB journal, 12(5), 1998, pp. 4464-4464
47. MOHAMED S; ALI S; DANDONA P; MOUSA SA
    ROLE OF ESTROGEN-RECEPTOR ON AV-BETA-3-MEDIATED CELL-ADHESION, MIGRATION AND SECRETION OF BFGF AND VEGF IN HUMAN ENDOTHELIAL AND ENDOMETRIAL CELLS
    The FASEB journal
    
    S. Mohamed et al., "ROLE OF ESTROGEN-RECEPTOR ON AV-BETA-3-MEDIATED CELL-ADHESION, MIGRATION AND SECRETION OF BFGF AND VEGF IN HUMAN ENDOTHELIAL AND ENDOMETRIAL CELLS", The FASEB journal, 12(5), 1998, pp. 4466-4466
48. BOZARTH JM; COHEN M; MOUSA SA
    ROLE OF ALPHA-V-BETA-3 INTEGRIN IN ENDOTHELIAL AND SMOOTH-MUSCLE CELL-MIGRATION - POTENTIAL ROLE IN CORONARY-ARTERY DISEASES
    The FASEB journal
    
    J.M. Bozarth et al., "ROLE OF ALPHA-V-BETA-3 INTEGRIN IN ENDOTHELIAL AND SMOOTH-MUSCLE CELL-MIGRATION - POTENTIAL ROLE IN CORONARY-ARTERY DISEASES", The FASEB journal, 12(4), 1998, pp. 2336-2336
49. MOUSA SA; FORSYTHE M; BOZARTH J; YOUSSEF A; WITYAK J; OLSON R; SIELECKI T
    XV454, A NOVEL NONPEPTIDE SMALL-MOLECULE PLATELET GIIB IIIA ANTAGONIST WITH COMPARABLE PLATELET ALPHA(IIB)BETA(3)-BINDING KINETICS TO C7E3/
    Journal of cardiovascular pharmacology
    
    S.A. Mousa et al., "XV454, A NOVEL NONPEPTIDE SMALL-MOLECULE PLATELET GIIB IIIA ANTAGONIST WITH COMPARABLE PLATELET ALPHA(IIB)BETA(3)-BINDING KINETICS TO C7E3/", Journal of cardiovascular pharmacology, 32(5), 1998, pp. 736-744
50. MOUSA SA; OLSON RE; BOZARTH JM; LORELLI W; FORSYTHE MS; RACANELLI A; GIBBS S; SCHLINGMAN K; BOZARTH T; KAPIL R; WITYAK J; SIELECKI TM; WEXLER RR; THOOLEN MJ; SLEE A; REILLY TM; ANDERSON PS; FRIEDMAN PA
    ORAL ANTIPLATELET EFFICACY AND SPECIFICITY OF A NOVEL NONPEPTIDE PLATELET GPIIB IIIA RECEPTOR ANTAGONIST, DMP-802/
    Journal of cardiovascular pharmacology
    
    S.A. Mousa et al., "ORAL ANTIPLATELET EFFICACY AND SPECIFICITY OF A NOVEL NONPEPTIDE PLATELET GPIIB IIIA RECEPTOR ANTAGONIST, DMP-802/", Journal of cardiovascular pharmacology, 32(2), 1998, pp. 169-176
51. MOUSA SA; FORSYTHE M; WITYAK J; BOZARTH J; MU DX
    INTRAVENOUS AND ORAL ANTIPLATELET ANTITHROMBOTIC EFFICACY AND SPECIFICITY OF XR300, A NOVEL NONPEPTIDE PLATELET GPIIB/IIIA ANTAGONIST/
    Journal of cardiovascular pharmacology
    
    S.A. Mousa et al., "INTRAVENOUS AND ORAL ANTIPLATELET ANTITHROMBOTIC EFFICACY AND SPECIFICITY OF XR300, A NOVEL NONPEPTIDE PLATELET GPIIB/IIIA ANTAGONIST/", Journal of cardiovascular pharmacology, 31(3), 1998, pp. 441-448
52. MOUSA SA; MU DX; HUSSAIN MA
    INTRANASAL ANTIPLATELET ANTITHROMBOTIC EFFICACY OF A NOVEL PLATELET GPIIB/IIIA RECEPTOR ANTAGONIST DMP755/
    Thrombosis research
    
    S.A. Mousa et al., "INTRANASAL ANTIPLATELET ANTITHROMBOTIC EFFICACY OF A NOVEL PLATELET GPIIB/IIIA RECEPTOR ANTAGONIST DMP755/", Thrombosis research, 92(3), 1998, pp. 115-124
53. PEDICORD DL; THOMAS BE; MOUSA SA; DICKER IB
    GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS INHIBIT THE DEVELOPMENT OFPLATELET PROCOAGULANT ACTIVITY/
    Thrombosis research
    
    D.L. Pedicord et al., "GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS INHIBIT THE DEVELOPMENT OFPLATELET PROCOAGULANT ACTIVITY/", Thrombosis research, 90(6), 1998, pp. 247-258
54. HANTGAN RR; MOUSA SA
    INHIBITION OF PLATELET-MEDIATED CLOT RETRACTION BY INTEGRIN ANTAGONISTS
    Thrombosis research
    
    R.R. Hantgan e S.A. Mousa, "INHIBITION OF PLATELET-MEDIATED CLOT RETRACTION BY INTEGRIN ANTAGONISTS", Thrombosis research, 89(6), 1998, pp. 271-279
55. MOUSA SA; BOZARTH J; YOUSSEF A; LEVINE B
    ORAL ANTIPLATELET EFFICACY OF THE PLATELET GPIIB IIIA ANTAGONIST, DMP754 IN NONHUMAN-PRIMATES/
    Thrombosis research
    
    S.A. Mousa et al., "ORAL ANTIPLATELET EFFICACY OF THE PLATELET GPIIB IIIA ANTAGONIST, DMP754 IN NONHUMAN-PRIMATES/", Thrombosis research, 89(5), 1998, pp. 217-225
56. TSAO PW; FORSYTHE MS; MOUSA SA
    DISSOCIATION BETWEEN THE ANTI-AGGREGATORY AND ANTI-SECRETORY EFFECTS OF PLATELET INTEGRIN ALPHA-IIB-BETA-3 (GPIIB IIIA) ANTAGONISTS, C7E3 AND DMP728 (VOL 88, PG 137, 1997)/
    Thrombosis research
    
    P.W. Tsao et al., "DISSOCIATION BETWEEN THE ANTI-AGGREGATORY AND ANTI-SECRETORY EFFECTS OF PLATELET INTEGRIN ALPHA-IIB-BETA-3 (GPIIB IIIA) ANTAGONISTS, C7E3 AND DMP728 (VOL 88, PG 137, 1997)/", Thrombosis research, 89(2), 1998, pp. 97-97
57. MOUSA SA; SOMASUNDARAM P; SUNG BH; BOZARTH JM; LORELLI W; WILSON MF
    ELEVATION OF CIRCULATING SMOOTH-MUSCLE CELL CHEMOATTRACTANTS MITOGENSAND ENDOTHELIAL-CELL DYSFUNCTION IN CONGESTIVE-HEART-FAILURE PATIENTS- POTENTIAL ROLE OF ALPHA-V-BETA-3 INTEGRIN/
    Naunyn-Schmiedeberg's archives of pharmacology
    
    S.A. Mousa et al., "ELEVATION OF CIRCULATING SMOOTH-MUSCLE CELL CHEMOATTRACTANTS MITOGENSAND ENDOTHELIAL-CELL DYSFUNCTION IN CONGESTIVE-HEART-FAILURE PATIENTS- POTENTIAL ROLE OF ALPHA-V-BETA-3 INTEGRIN/", Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4919-4919
58. MOUSA SA; MU DX
    ANTITHROMBOTIC EFFICACY OF PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS AS COMPARED TO OTHER ANTIPLATELET AND ANTICOAGULANT STRATEGIES/
    Naunyn-Schmiedeberg's archives of pharmacology
    
    S.A. Mousa e D.X. Mu, "ANTITHROMBOTIC EFFICACY OF PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS AS COMPARED TO OTHER ANTIPLATELET AND ANTICOAGULANT STRATEGIES/", Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 5217-5217
59. MOUSA SA; BOZARTH JM; BENNETT JS
    ACTIVATION-DEPENDENT ALPHA-V-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN
    Naunyn-Schmiedeberg's archives of pharmacology
    
    S.A. Mousa et al., "ACTIVATION-DEPENDENT ALPHA-V-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN", Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4216-4216
60. MOUSA SA; BOZARTH JM; LORELLI W; FORSYTHE MS; THOOLEN MJMC; SLEE AM; REILLY TM; FRIEDMAN PA
    ANTIPLATELET EFFICACY OF XV459, A NOVEL NONPEPTIDE PLATELET GPIIB IIAANTAGONIST - COMPARATIVE PLATELET BINDING PROFILES WITH C7E3/
    The Journal of pharmacology and experimental therapeutics
    
    S.A. Mousa et al., "ANTIPLATELET EFFICACY OF XV459, A NOVEL NONPEPTIDE PLATELET GPIIB IIAANTAGONIST - COMPARATIVE PLATELET BINDING PROFILES WITH C7E3/", The Journal of pharmacology and experimental therapeutics, 286(3), 1998, pp. 1277-1284
61. MICHAELIS W; TURLAPATY P; GRAY J; FISKE WD; FAULKNER E; KORNBAUSER D; MOUSA SA
    PHARMACODYNAMICS AND PHARMACOKINETICS OF DMP-728, A PLATELET GPIIB IIIA ANTAGONIST, IN HEALTHY-SUBJECTS/
    Clinical pharmacology and therapeutics
    
    W. Michaelis et al., "PHARMACODYNAMICS AND PHARMACOKINETICS OF DMP-728, A PLATELET GPIIB IIIA ANTAGONIST, IN HEALTHY-SUBJECTS/", Clinical pharmacology and therapeutics, 63(3), 1998, pp. 384-392
62. MOUSA SA; BOZARTH J; DEGRADO W; BENNETT J
    ACTIVATION-DEPENDENT ALPHA-V-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN - POTENTIAL SURROGATE FOR MONITORING ANTI-ALPHA-V-BETA-3 INTEGRIN EFFICACY
    Circulation
    
    S.A. Mousa et al., "ACTIVATION-DEPENDENT ALPHA-V-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN - POTENTIAL SURROGATE FOR MONITORING ANTI-ALPHA-V-BETA-3 INTEGRIN EFFICACY", Circulation, 98(17), 1998, pp. 2753-2753
63. MOUSA SA; DEGRADO W; HARRISON D; HOLMES D; SRIVATSA SS
    DISCOVERY OF A KEY ROLE FOR THE ALPHA-NU-BETA-3 INTEGRIN IN ACUTE ANDDELAYED VASCULAR OCCLUSION AND REOCCLUSION WITHOUT EFFECTS ON HEMOSTASIS
    Circulation
    
    S.A. Mousa et al., "DISCOVERY OF A KEY ROLE FOR THE ALPHA-NU-BETA-3 INTEGRIN IN ACUTE ANDDELAYED VASCULAR OCCLUSION AND REOCCLUSION WITHOUT EFFECTS ON HEMOSTASIS", Circulation, 98(17), 1998, pp. 2762-2762
64. RABBANI R; LEBRETON H; KHURANA C; PLOW EF; MOUSA SA; LINCOFF AM
    THE ROLE OF INTEGRINS ALPHA(V)BETA(3) AND ALPHA(ILB)BETA(3) IN AN EXPERIMENTAL ARTERIAL INJURY MODEL
    Circulation
    
    R. Rabbani et al., "THE ROLE OF INTEGRINS ALPHA(V)BETA(3) AND ALPHA(ILB)BETA(3) IN AN EXPERIMENTAL ARTERIAL INJURY MODEL", Circulation, 98(17), 1998, pp. 2813-2813
65. VARNER JA; MOUSA SA
    ANTAGONISTS OF VASCULAR CELL INTEGRIN ALPHA-5-BETA-1 INHIBIT ANGIOGENESIS
    Circulation
    
    J.A. Varner e S.A. Mousa, "ANTAGONISTS OF VASCULAR CELL INTEGRIN ALPHA-5-BETA-1 INHIBIT ANGIOGENESIS", Circulation, 98(17), 1998, pp. 4166-4166
66. MOUSA SA; CHERESH DA
    RECENT ADVANCES IN CELL-ADHESION MOLECULES AND EXTRACELLULAR-MATRIX PROTEINS - POTENTIAL CLINICAL IMPLICATIONS
    Drug discovery today
    
    S.A. Mousa e D.A. Cheresh, "RECENT ADVANCES IN CELL-ADHESION MOLECULES AND EXTRACELLULAR-MATRIX PROTEINS - POTENTIAL CLINICAL IMPLICATIONS", Drug discovery today, 2(5), 1997, pp. 187-199
67. CORBETT JW; GRACIANI NR; MOUSA SA; DEGRADO WF
    SOLID-PHASE SYNTHESIS OF A SELECTIVE ALPHA(V)BETA(3) INTEGRIN ANTAGONIST LIBRARY
    Bioorganic & medicinal chemistry letters
    
    J.W. Corbett et al., "SOLID-PHASE SYNTHESIS OF A SELECTIVE ALPHA(V)BETA(3) INTEGRIN ANTAGONIST LIBRARY", Bioorganic & medicinal chemistry letters, 7(11), 1997, pp. 1371-1376
68. SRIVATSA SS; REILLY TM; HOLMES DR; SCHWARTZ RS; MOUSA SA
    COMBINED ALPHA-V-BETA-3 AND PLATELET IIB IIIA INTEGRIN BLOCKADE POTENTLY LIMITS NEOINTIMAL HYPERPLASIA AND LUMEN STENOSIS IN THE PORCINE CORONARY INJURY MODEL/
    Journal of the American College of Cardiology
    
    S.S. Srivatsa et al., "COMBINED ALPHA-V-BETA-3 AND PLATELET IIB IIIA INTEGRIN BLOCKADE POTENTLY LIMITS NEOINTIMAL HYPERPLASIA AND LUMEN STENOSIS IN THE PORCINE CORONARY INJURY MODEL/", Journal of the American College of Cardiology, 29(2), 1997, pp. 7014-7014
69. REILLY TM; RACANELLI AL; OLSON RE; WITYAK J; WEXLER RR; HAUSNER EA; THOOLEN MJ; MOUSA SA
    ANTIPLATELET EFFICACY OF ORALLY-ADMINISTERED DMP802, A GPIIB IIIA RECEPTOR ANTAGONIST, IN THE CONSCIOUS DOG/
    Journal of the American College of Cardiology
    
    T.M. Reilly et al., "ANTIPLATELET EFFICACY OF ORALLY-ADMINISTERED DMP802, A GPIIB IIIA RECEPTOR ANTAGONIST, IN THE CONSCIOUS DOG/", Journal of the American College of Cardiology, 29(2), 1997, pp. 7122-7122
70. SRIVATSA SS; TSAO P; HOLMES DR; SCHWARTZ RS; MOUSA SA
    TEMPORAL AND SPATIAL VARIATION IN ALPHA-V-BETA-3 INTEGRIN EXPRESSION FOLLOWING DEEP ARTERIAL INJURY IN THE PORCINE CORONARY RESTENOSIS MODEL
    Journal of the American College of Cardiology
    
    S.S. Srivatsa et al., "TEMPORAL AND SPATIAL VARIATION IN ALPHA-V-BETA-3 INTEGRIN EXPRESSION FOLLOWING DEEP ARTERIAL INJURY IN THE PORCINE CORONARY RESTENOSIS MODEL", Journal of the American College of Cardiology, 29(2), 1997, pp. 60110-60110
71. MOUSA SA; MU DX; HUSSAIN M
    INTRANASAL ANTIPLATELET ANTITHROMBOTIC EFFICACY OF THE PLATELET GPIIB/IIIA ANTAGONIST, DMP754/
    Journal of the American College of Cardiology
    
    S.A. Mousa et al., "INTRANASAL ANTIPLATELET ANTITHROMBOTIC EFFICACY OF THE PLATELET GPIIB/IIIA ANTAGONIST, DMP754/", Journal of the American College of Cardiology, 29(2), 1997, pp. 60112-60112
72. MOUSA SA; MU DX; REILLY TM
    INTRAVENOUS AND ORAL ANTITHROMBOTIC EFFICACY OF A NOVEL NONPEPTIDE ANTIPLATELET GPIIB IIIA ANTAGONIST, DMP-754 AS COMPARED TO OTHER ANTIPLATELET AND ANTICOAGULANT STRATEGIES/
    Thrombosis and haemostasis
    
    S.A. Mousa et al., "INTRAVENOUS AND ORAL ANTITHROMBOTIC EFFICACY OF A NOVEL NONPEPTIDE ANTIPLATELET GPIIB IIIA ANTAGONIST, DMP-754 AS COMPARED TO OTHER ANTIPLATELET AND ANTICOAGULANT STRATEGIES/", Thrombosis and haemostasis, 1997, pp. 1600-1600
73. PEDICORD DL; MOUSA SA; DICKER IB
    PLATELET GPIIBIIIA RECEPTOR ANTAGONISTS INHIBIT PLATELET PROCOAGULANTACTIVITY
    Thrombosis and haemostasis
    
    D.L. Pedicord et al., "PLATELET GPIIBIIIA RECEPTOR ANTAGONISTS INHIBIT PLATELET PROCOAGULANTACTIVITY", Thrombosis and haemostasis, 1997, pp. 2693-2693
74. MOUSA SA; BOZARTH J; FORSYTHE M; XUE CB; WITYAK J; OLSON R; THOOLEN M; REILLY T
    DISCOVERY OF NOVEL ORALLY-ACTIVE NONPEPTIDE ANTIPLATELET GPIIB IIIA ANTAGONIST, DMP754 - COMPARATIVE PLATELET BINDING-AFFINITY PROFILES WITH DMP728 AND C7E3/
    Thrombosis and haemostasis
    
    S.A. Mousa et al., "DISCOVERY OF NOVEL ORALLY-ACTIVE NONPEPTIDE ANTIPLATELET GPIIB IIIA ANTAGONIST, DMP754 - COMPARATIVE PLATELET BINDING-AFFINITY PROFILES WITH DMP728 AND C7E3/", Thrombosis and haemostasis, 1997, pp. 2707-2707
75. TSAO PW; FORSYTHE MS; MOUSA SA
    DISSOCIATION BETWEEN THE ANTI-AGGREGATORY AND ANTI-SECRETORY EFFECTS OF PLATELET INTEGRIN ALPHA(IIB)BETA(3) (GPIIB IIIA) ANTAGONISTS, C7E3 AND DMP728/
    Thrombosis research
    
    P.W. Tsao et al., "DISSOCIATION BETWEEN THE ANTI-AGGREGATORY AND ANTI-SECRETORY EFFECTS OF PLATELET INTEGRIN ALPHA(IIB)BETA(3) (GPIIB IIIA) ANTAGONISTS, C7E3 AND DMP728/", Thrombosis research, 88(2), 1997, pp. 137-146
76. KAPIL RP; EMM TA; MOUSA SA; PADOVANI PK; QUON CY; LAM GN
    BIOLOGICAL MATRIX-DEPENDENT PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS OF A NOVEL PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST, XU063, IN BEAGLE DOGS/
    Thrombosis research
    
    R.P. Kapil et al., "BIOLOGICAL MATRIX-DEPENDENT PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS OF A NOVEL PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST, XU063, IN BEAGLE DOGS/", Thrombosis research, 86(3), 1997, pp. 221-232
77. MOUSA SA; MU DX; LUCCHESI BR
    PREVENTION OF CAROTID-ARTERY THROMBOSIS BY ORAL PLATELET GPIIB IIIA ANTAGONIST IN DOGS/
    Stroke
    
    S.A. Mousa et al., "PREVENTION OF CAROTID-ARTERY THROMBOSIS BY ORAL PLATELET GPIIB IIIA ANTAGONIST IN DOGS/", Stroke, 28(4), 1997, pp. 830-835
78. HUSSAIN MA; AUNGST BJ; KAPIL R; MOUSA SA
    INTRANASAL ABSORPTION OF THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST, DMP-755, AND THE EFFECT OF ANESTHESIA ON NASAL BIOAVAILABILITY/
    Journal of pharmaceutical sciences
    
    M.A. Hussain et al., "INTRANASAL ABSORPTION OF THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST, DMP-755, AND THE EFFECT OF ANESTHESIA ON NASAL BIOAVAILABILITY/", Journal of pharmaceutical sciences, 86(12), 1997, pp. 1358-1360
79. WITYAK J; SIELECKI TM; PINTO DJ; EMMETT G; SZE JY; LIU J; TOBIN AE; WANG SG; JIANG B; MA P; MOUSA SA; OLSON RE; WEXLER RR
    THE DISCOVERY OF POTENT ISOXAZOLINE GLYCOPROTEIN-IIB IIIA RECEPTOR ANTAGONISTS. (VOL 40, PG 53, 1997)/
    Journal of medicinal chemistry
    
    J. Wityak et al., "THE DISCOVERY OF POTENT ISOXAZOLINE GLYCOPROTEIN-IIB IIIA RECEPTOR ANTAGONISTS. (VOL 40, PG 53, 1997)/", Journal of medicinal chemistry, 40(8), 1997, pp. 1292-1292
80. XUE CB; WITYAK J; SIELECKI TM; PINTO DJ; BATT DG; CAIN GA; SWORIN M; ROCKWELL AL; RODERICK JJ; WANG SG; ORWAT MJ; FRIETZE WE; BOSTROM LL; LIU J; HIGLEY CA; RANKIN FW; TOBIN AE; EMMETT G; LALKA GK; SZE JY; DIMEO SV; MOUSA SA; THOOLEN MJ; RACANELLI AL; HAUSNER EA; REILLY TM; DEGRADO WF; WEXLER RR; OLSON RE
    DISCOVERY OF AN ORALLY-ACTIVE SERIES OF ISOXAZOLINE GLYCOPROTEIN IIB IIIA ANTAGONISTS/
    Journal of medicinal chemistry
    
    C.B. Xue et al., "DISCOVERY OF AN ORALLY-ACTIVE SERIES OF ISOXAZOLINE GLYCOPROTEIN IIB IIIA ANTAGONISTS/", Journal of medicinal chemistry, 40(13), 1997, pp. 2064-2084
81. WITYAK J; SIELECKI TM; PINTO DJ; EMMETT G; SZE JY; LIU J; TOBIN AE; WANG SA; JIANG B; MA P; MOUSA SA; WEXLER RR; OLSON RE
    DISCOVERY OF POTENT ISOXAZOLINE GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS/
    Journal of medicinal chemistry
    
    J. Wityak et al., "DISCOVERY OF POTENT ISOXAZOLINE GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS/", Journal of medicinal chemistry, 40(1), 1997, pp. 50-60
82. BENNETT JS; CHAN C; VILAIRE G; MOUSA SA; DEGRADO WF
    AGONIST-ACTIVATED ALPHA-NU-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS TO THE MATRIX PROTEIN OSTEOPONTIN
    The Journal of biological chemistry
    
    J.S. Bennett et al., "AGONIST-ACTIVATED ALPHA-NU-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS TO THE MATRIX PROTEIN OSTEOPONTIN", The Journal of biological chemistry, 272(13), 1997, pp. 8137-8140
83. SCHAFER M; MOUSA SA; STEIN C
    CORTICOTROPIN-RELEASING FACTOR IN ANTINOCICEPTION AND INFLAMMATION
    European journal of pharmacology
    
    M. Schafer et al., "CORTICOTROPIN-RELEASING FACTOR IN ANTINOCICEPTION AND INFLAMMATION", European journal of pharmacology, 323(1), 1997, pp. 1-10
84. PEDICORD DB; THOMAS BE; MOUSA SA; DICKER IB
    PLATELET GPIIBIIIA RECEPTOR ANTAGONISTS INHIBIT PLATELET PROCOAGULANTACTIVITY
    Circulation
    
    D.B. Pedicord et al., "PLATELET GPIIBIIIA RECEPTOR ANTAGONISTS INHIBIT PLATELET PROCOAGULANTACTIVITY", Circulation, 96(8), 1997, pp. 14-14
85. MOUSA SA; BOZARTH JM; DEGRADO W; BENNETT JS
    ACTIVATION-DEPENDENT ALPHA-V BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN
    Circulation
    
    S.A. Mousa et al., "ACTIVATION-DEPENDENT ALPHA-V BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN", Circulation, 96(8), 1997, pp. 623-623
86. MOUSA SA; BOZARTH JM; FORSYTHE MS; THOOLEN M; REILLY TM; WITYAK J; OLSON RE; SIELECKI TM
    XV454, A NOVEL NONPEPTIDE ANTIPLATELET AGENT WITH COMPARABLE PLATELETALPHA-IIB-BETA-3 BINDING-KINETICS TO C7E3 AND LONG-LASTING ANTIPLATELET EFFICACY AFTER SINGLE INTRAVENOUS OR ORAL-ADMINISTRATION IN NONHUMAN-PRIMATES
    Circulation
    
    S.A. Mousa et al., "XV454, A NOVEL NONPEPTIDE ANTIPLATELET AGENT WITH COMPARABLE PLATELETALPHA-IIB-BETA-3 BINDING-KINETICS TO C7E3 AND LONG-LASTING ANTIPLATELET EFFICACY AFTER SINGLE INTRAVENOUS OR ORAL-ADMINISTRATION IN NONHUMAN-PRIMATES", Circulation, 96(8), 1997, pp. 928-928
87. SRIVATSA SS; FITZPATRICK LA; TSAO PW; REILLY TM; HOLMES DR; SCHWARTZ RS; MOUSA SA
    SELECTIVE ALPHA-V-BETA-3 INTEGRIN BLOCKADE POTENTLY LIMITS NEOINTIMALHYPERPLASIA AND LUMEN STENOSIS FOLLOWING DEEP CORONARY ARTERIAL STENTINJURY - EVIDENCE FOR THE FUNCTIONAL IMPORTANCE OF INTEGRIN ALPHA-V-BETA-3 AND OSTEOPONTIN EXPRESSION DURING NEOINTIMA FORMATION
    Cardiovascular Research
    
    S.S. Srivatsa et al., "SELECTIVE ALPHA-V-BETA-3 INTEGRIN BLOCKADE POTENTLY LIMITS NEOINTIMALHYPERPLASIA AND LUMEN STENOSIS FOLLOWING DEEP CORONARY ARTERIAL STENTINJURY - EVIDENCE FOR THE FUNCTIONAL IMPORTANCE OF INTEGRIN ALPHA-V-BETA-3 AND OSTEOPONTIN EXPRESSION DURING NEOINTIMA FORMATION", Cardiovascular Research, 36(3), 1997, pp. 408-428
88. MOUSA SA
    ANGIOGENESIS PROMOTERS AND INHIBITORS - POTENTIAL THERAPEUTIC IMPLICATIONS
    Molecular medicine today
    
    S.A. Mousa, "ANGIOGENESIS PROMOTERS AND INHIBITORS - POTENTIAL THERAPEUTIC IMPLICATIONS", Molecular medicine today, 2(4), 1996, pp. 140-142
89. MOUSA SA; FORSYTHE M; LORELLI W; BOZARTH J; XUE CB; WITYAK J; SIELECKI TM; OLSON RE; DEGRADO W; KAPIL R; HUSSAIN M; WEXLER R; THOOLEN MJ; REILLY TM
    NOVEL NONPEPTIDE ANTIPLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST, DMP754 - RECEPTOR-BINDING AFFINITY AND SPECIFICITY/
    Coronary artery disease
    
    S.A. Mousa et al., "NOVEL NONPEPTIDE ANTIPLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST, DMP754 - RECEPTOR-BINDING AFFINITY AND SPECIFICITY/", Coronary artery disease, 7(10), 1996, pp. 767-774
90. MU DX; MOUSA SA
    ANIMAL-MODEL OF ARTERIAL AND VENOUS THROMBOSIS IN DOGS - ASSESSMENT OF THE EFFICACY OF VARIOUS ANTITHROMBOTIC STRATEGIES
    The FASEB journal
    
    D.X. Mu e S.A. Mousa, "ANIMAL-MODEL OF ARTERIAL AND VENOUS THROMBOSIS IN DOGS - ASSESSMENT OF THE EFFICACY OF VARIOUS ANTITHROMBOTIC STRATEGIES", The FASEB journal, 10(3), 1996, pp. 2506-2506
91. MOUSA SA; MU DX
    ANTITHROMBOTIC EFFICACY OF NITRIC-OXIDE DONOR IN ARTERIAL AND VENOUS THROMBOSIS MODEL IN PIGS
    The FASEB journal
    
    S.A. Mousa e D.X. Mu, "ANTITHROMBOTIC EFFICACY OF NITRIC-OXIDE DONOR IN ARTERIAL AND VENOUS THROMBOSIS MODEL IN PIGS", The FASEB journal, 10(3), 1996, pp. 3282-3282
92. MOUSA SA; FORSYTHE M; REILLY TM
    PLATELET - ENDOTHELIAL-CELL INTERACTIONS IN MEDIATING THE RELEASE OF PLASMINOGEN-ACTIVATOR INHIBITOR-1
    Biochemical archives
    
    S.A. Mousa et al., "PLATELET - ENDOTHELIAL-CELL INTERACTIONS IN MEDIATING THE RELEASE OF PLASMINOGEN-ACTIVATOR INHIBITOR-1", Biochemical archives, 12(2), 1996, pp. 43-53
93. AUNGST BJ; SAITOH H; BURCHAM DL; HUANG SM; MOUSA SA; HUSSAIN MA
    ENHANCEMENT OF THE INTESTINAL-ABSORPTION OF PEPTIDES AND NONPEPTIDES
    Journal of controlled release
    
    B.J. Aungst et al., "ENHANCEMENT OF THE INTESTINAL-ABSORPTION OF PEPTIDES AND NONPEPTIDES", Journal of controlled release, 41(1-2), 1996, pp. 19-31
94. LUNA J; TOBE T; MOUSA SA; REILLY TM; CAMPOCHIARO PA
    ANTAGONISTS OF INTEGRIN ALPHA(V)BETA(3) INHIBIT RETINAL NEOVASCULARIZATION IN A MURINE MODEL
    Laboratory investigation
    
    J. Luna et al., "ANTAGONISTS OF INTEGRIN ALPHA(V)BETA(3) INHIBIT RETINAL NEOVASCULARIZATION IN A MURINE MODEL", Laboratory investigation, 75(4), 1996, pp. 563-573
95. BURGESS K; LIM D; MOUSA SA
    SYNTHESIS AND SOLUTION CONFORMATION OF CYCLO[RGDRGD] - A CYCLIC PEPTIDE WITH SELECTIVITY FOR THE ALPHA-V-BETA-3 RECEPTOR
    Journal of medicinal chemistry
    
    K. Burgess et al., "SYNTHESIS AND SOLUTION CONFORMATION OF CYCLO[RGDRGD] - A CYCLIC PEPTIDE WITH SELECTIVITY FOR THE ALPHA-V-BETA-3 RECEPTOR", Journal of medicinal chemistry, 39(22), 1996, pp. 4520-4526
96. MOUSA SA; SCHAFER M; MITCHELL WM; HASSAN AHS; STEIN C
    LOCAL UP-REGULATION OF CORTICOTROPIN-RELEASING HORMONE AND INTERLEUKIN-1 RECEPTORS IN RATS WITH PAINFUL HINDLIMB INFLAMMATION
    European journal of pharmacology
    
    S.A. Mousa et al., "LOCAL UP-REGULATION OF CORTICOTROPIN-RELEASING HORMONE AND INTERLEUKIN-1 RECEPTORS IN RATS WITH PAINFUL HINDLIMB INFLAMMATION", European journal of pharmacology, 311(2-3), 1996, pp. 221-231
97. SRIVATSA SS; REILLY TM; HOLMES DR; SCHWARTZ RS; MOUSA SA
    SELECTIVE ALPHA-V BETA-3 INTEGRIN BLOCKADE LIMITS NEOINTIMAL HYPERPLASIA AND LUMEN STENOSIS IN THE STENTED PORCINE CORONARY-ARTERY INJURY MODEL
    Circulation
    
    S.S. Srivatsa et al., "SELECTIVE ALPHA-V BETA-3 INTEGRIN BLOCKADE LIMITS NEOINTIMAL HYPERPLASIA AND LUMEN STENOSIS IN THE STENTED PORCINE CORONARY-ARTERY INJURY MODEL", Circulation, 94(8), 1996, pp. 231-231
98. RACANELLI AL; KAPIL RP; MOUSA SA; REILLY TM; THOOLEN MJ
    ORAL ANTIPLATELET EFFECTS OF DMP-754 IN DOGS AND NONHUMAN-PRIMATES
    Circulation
    
    A.L. Racanelli et al., "ORAL ANTIPLATELET EFFECTS OF DMP-754 IN DOGS AND NONHUMAN-PRIMATES", Circulation, 94(8), 1996, pp. 565-565
99. MOUSA SA; BOZARTH J; FORSYTHE M; WITYAK J; REILLY TM; MU DX
    INTRAVENOUS AND ORAL ANTIPLATELET ANTITHROMBOTIC EFFICACY AND SPECIFICITY OF XR300, A NOVEL NON PEPTIDE PLATELET GPIIB/IIIA ANTAGONIST/
    Circulation
    
    S.A. Mousa et al., "INTRAVENOUS AND ORAL ANTIPLATELET ANTITHROMBOTIC EFFICACY AND SPECIFICITY OF XR300, A NOVEL NON PEPTIDE PLATELET GPIIB/IIIA ANTAGONIST/", Circulation, 94(8), 1996, pp. 569-569
100. MOUSA SA; BOZARTH J; FORSYTHE M; XUE CB; WITYAK J; OLSON R; THOOLEN MJ; REILLY TM
     DISCOVERY OF A NOVEL NON PEPTIDE ANTIPLATELET GPIIB IIIA RECEPTOR ANTAGONIST, DMP-754 - RECEPTOR-BINDING AFFINITY AND SPECIFICITY/
     Circulation
     
     S.A. Mousa et al., "DISCOVERY OF A NOVEL NON PEPTIDE ANTIPLATELET GPIIB IIIA RECEPTOR ANTAGONIST, DMP-754 - RECEPTOR-BINDING AFFINITY AND SPECIFICITY/", Circulation, 94(8), 1996, pp. 3006-3006